Table 2 Univariate and multivariate analysis of factors associated with time to recurrence and overall survival in two independent cohorts of human HCC

Univariate Analysis

 Age

0.982(0.969–0.995)

0.006

0.981(0.968–0.994)

0.005

 Sex (male versus female)

0.925(0.629–1.360)

0.692

0.873(0.593–1.286)

0.492

 Serum AFP (> 20 versus ≤ 20 ng/ml)

1.349(0.943–1.931)

0.102

1.405(0.970–2.036)

0.072

 HBV infection (yes versus no)

0.792(0.564–1.112)

0.178

0.767(0.543–1.081)

0.130

 Cirrhosis ( present versus absent)

0.903(0.647–1.259)

0.548

0.876(0.625–1.228)

0.442

 Child–pugh score (B versus A)

0.959(0.675–1.364)

0.818

0.948(0.661–1.358)

0.769

 Tumor number (multiple versus single)

1.961(1.447–2.656)

 < 0.001

2.048(1.503–2.791)

 < 0.001

 Maximal tumor size (> 5 versus ≤ 5 cm)

1.510(1.103–2.066)

0.010

1.573(1.139–2.173)

0.006

 Tumor encapsulation (absent versus present)

3.422(2.507–4.669)

 < 0.001

3.584(2.607–4.927)

 < 0.001

 Microvascular invasion (present versus absent)

3.111(2.280–4.245)

 < 0.001

3.315(2.411–4.558)

 < 0.001

 Tumor differentiation (III- IV versus I-II)

3.155(2.243–4.437)

 < 0.001

3.363(2.385–4.743)

 < 0.001

 TNM stage (III versus I-II)

6.680(4.741–9.414)

 < 0.001

7.093(5.015–10.033)

 < 0.001

 ETV1 (positive versus negative)

2.059(1.519–2.792)

 < 0.001

2.143(1.571–2.922)

 < 0.001

Multivariate analysis

 Tumor number (multiple versus single)

1.441(0.925–2.247)

0.106

1.530(0.973–2.406)

0.066

 Maximal tumor size (> 5 versus ≤ 5 cm)

1.417(0.966–2.078)

0.075

1.465(0.986–2.175)

0.059

 Tumor encapsulation (absent versus present)

1.335(0.840–2.121)

0.222

1.289(0.803–2.072)

0.293

 Microvascular invasion (present versus absent)

1.663(1.082–2.556)

0.020

1.808(1.168–2.800)

0.008

 Tumor differentiation (III- IV versus I-II)

1.569(1.075–2.288)

0.019

1.651(1.131–2.411)

0.009

 TNM stage (III versus I-II)

3.004(1.815–4.971)

 < 0.001

3.004(1.796–5.026)

 < 0.001

 ETV1 (positive versus negative)

1.651(1.201–2.269)

0.002

1.748(1.266–2.415)

0.001

Univariate Analysis

 Age

0.992(0.977–1.008)

0.327

0.988(0.972–1.003)

0.117

 Sex (male versus female)

1.080(0.695–1.678)

0.732

0.987(0.645–1.510)

0.952

 Serum AFP (> 20 versus ≤ 20 ng/ml)

0.951(0.657–1.377)

0.789

0.907(0.631–1.302)

0.595

 HBV infection (yes versus no)

2.203(1.380–3.519)

0.001

2.305(1.444–3.679)

 < 0.001

 Cirrhosis ( present versus absent)

1.212(0.856–1.716)

0.278

1.242(0.878–1.756)

0.221

 Child–pugh score (B versus A)

1.359(0.924–1.999)

0.120

1.339(0.911–1.969)

0.137

 Tumor number (multiple versus single)

2.397(1.726–3.329)

 < 0.001

2.391(1.724–3.316)

 < 0.001

 Maximal tumor size (> 5 versus ≤ 5 cm)

2.511(1.839–3.429)

 < 0.001

2.317(1.705–3.151)

 < 0.001

 Tumor encapsulation (absent versus present)

3.058(2.239–4.177)

 < 0.001

2.897(2.127–3.946)

 < 0.001

 Microvascular invasion (present versus absent)

2.213(1.624–3.016)

 < 0.001

2.268(1.668–3.083)

 < 0.001

 Tumor differentiation (III- IV versus I-II)

3.539(2.561–4.890)

 < 0.001

3.444(2.503–4.739)

 < 0.001

 TNM stage (III versus I-II)

5.481(3.913–7.675)

 < 0.001

5.875(4.196–8.225)

 < 0.001

 ETV1 (positive versus negative)

2.218(1.629–3.020)

 < 0.001

2.220(1.635–3.014)

 < 0.001

Multivariate analysis

 Tumor number (multiple versus single)

1.272(0.852–1.898)

0.239

1.236(0.823–1.857)

0.307

 Maximal tumor size (> 5 versus ≤ 5 cm)

1.146(0.790–1.662)

0.473

1.013(0.704–1.456)

0.946

 Tumor encapsulation (absent versus present)

1.495(0.986–2.269)

0.059

1.394(0.923–2.105)

0.114

 Microvascular invasion (present versus absent)

1.475(0.995–2.188)

0.053

1.625(1.101–2.399)

0.015

 Tumor differentiation (III- IV versus I-II)

1.727(1.195–2.495)

0.004

1.696(1.180–2.437)

0.004

 TNM stage (III versus I-II)

2.968(1.885–4.672)

 < 0.001

3.518(2.230–5.550)

 < 0.001

 ETV1 (positive versus negative)

1.636(1.173–2.283)

0.004

1.638(1.180–2.274)

0.003